

This invention pertains to compounds which specifically inhibit the adenosine A_1 , A_{2A} , and A_3 receptors and the use of these compounds to treat a disease associated with A_1 , A_{2A} , and A_3 adenosine receptors in a subjects, comprising administering to the subject a therapeutically effective amount of the compounds.